Email Updates

Search form

You are here

HVTN 114

Status
Ongoing
Phase
I
Principal Investigator(s)
Harriet L. Robinson, GeoVax
Objective

To evaluate the immunogenicity of AIDSVAX® B/E bivalent gp120 vaccine and MVA/HIV62B in healthy, HIV-1 uninfected adult participants who previously received MVA/HIV62B in DNA/MVA or MVA/MVA regimens in HVTN 205.

*Trial is in follow-up*

Prevention Option(s)
HIV Vaccine
Study Design
Randomized
Arms and Assigned Interventions
Description
HVTN 114 w GeoVax MVA62B vaccine with or without a gp120 protein vaccine, AIDSVAX® B/E
Products
AIDSVAX
gp120
MVA
ARMs
Experimental
Clade
B
E
Trial Sponsors
HVTN
Product Developers
GeoVax
February 2017
October 2019
Enrollment
100
18
Years
55
Years
Sites

Site(s) - Atlanta

Atlanta, GA
United States of America

University of Alabama at Birmingham

Birmingham, Alabama
United States of America

Brigham and Women's Hospital CRS

Boston, Massachusetts
United States of America

Columbia P&S CRS

New York, NY
United States of America

New York Blood Center

New York, New York
United States of America

Site(s) - Nashville

Nashville, Tennessee
United States of America

University of Rochester HVTN CRS

Rochester, New York
United States of America

Site(s) - Seattle

Seattle, Washington
United States of America

San Francisco Department of Public Health

San Francisco, California
United States of America

Site(s) - Iquitos

Peru

Barranco CRS

Lima
Peru